The Clinical Pharmacology Research Center, Research Institute and Departments of Pharmacy and Medicine, Bassett Healthcare, Cooperstown, New York, USA,
Clin Drug Investig. 2000;20(2):135-42. doi: 10.2165/00044011-200020020-00008.
Azithromycin, fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole; TMP/SMX) are all agents that are utilised for the treatment and/or prophylaxis of opportunistic infections in patients with AIDS.
To characterise the potential for an interaction when azithromycin is coadministered with cotrimoxazole or with fluconazole.
Two separate nonblind randomised studies were conducted in healthy volunteers. During the fluconazole study the potential for fluconazole to adversely affect the pharmacokinetics of azithromycin was also studied.
24 (cotrimoxazole) and 18 (fluconazole) healthy male and female volunteers.
The results of both studies indicated that neither the peak concentrations of nor the exposures (area under the concentration-time curve) to the test drugs were changed when azithromycin was coadministered. In addition, fluconazole did not significantly alter the pharmacokinetic parameters of azithromycin.
Azithromycin does not alter the bioavailability of either cotrimoxazole or fluconazole.
阿奇霉素、氟康唑和复方磺胺甲噁唑(甲氧苄啶-磺胺甲噁唑;TMP/SMX)都是用于治疗和/或预防艾滋病患者机会性感染的药物。
描述阿奇霉素与复方磺胺甲噁唑或氟康唑同时使用时可能发生的相互作用。
在健康志愿者中进行了两项独立的非盲随机研究。在氟康唑研究中,还研究了氟康唑是否会对阿奇霉素的药代动力学产生不利影响。
24 名(复方磺胺甲噁唑)和 18 名(氟康唑)健康男性和女性志愿者。
两项研究的结果均表明,当阿奇霉素与复方磺胺甲噁唑或氟康唑同时使用时,试验药物的峰值浓度和暴露量(浓度-时间曲线下面积)均未发生变化。此外,氟康唑并未显著改变阿奇霉素的药代动力学参数。
阿奇霉素不会改变复方磺胺甲噁唑或氟康唑的生物利用度。